MedTrace Logo

Drug-drug Interactions Between DWP14012 and Aspirin in Healthy Subjects

NCT05304845 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-04-05

No results posted yet for this study

Summary

This is a randomized, open-label study to evaluate the safety/tolerability and PK/PD drug-drug interactions between DWP14012 and aspirin when administered in combination.

Conditions

  • Drug Drug Interaction

Interventions

DRUG

DWP14012

Potassium-competitive acid blocker

DRUG

Aspirin

acetylsalicylic acid

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • In Jin Jang, MD, PhD · Seoul National University

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2022-05-22
Completion
2022-05-22

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05304845 on ClinicalTrials.gov